SHANG-YI HUANGLin, Hsiu-HsiaHsiu-HsiaLinCHUNG-WU LINLi, Chi-ChengChi-ChengLiMING YAOJIH-LUH TANGHSIN-AN HOUWOEI TSAYChou, Sheng-JeSheng-JeChouChieh-Lung ChengHWEI-FANG TIEN2020-12-092020-12-092016-09-201949-2553https://scholars.lib.ntu.edu.tw/handle/123456789/525050Autologous hematopoietic stem cell transplantation (AuHSCT) is standard in treating eligible multiple myeloma (MM) patients. However, the outcome after treatment is highly variable. We used ELISA to analyze the levels of soluble PD-L1 (suPD-L1) in bone marrow (BM) plasma from 61 patients with MM at 100 days after AuHSCT. Patients were classified into high (H) and normal-to-low (NL) groups depending on their suPD-L1 levels. Among patients who had a very good partial response (VGPR) or better after AuHSCT, those in the H-group had a shorter response period (RpSCT) as well as shorter overall survival (OS) than those in the NL-group. Multivariate analyses confirmed that a high suPD-L1 level and high-risk cytogenetic abnormalities are independent factors for RpSCT. Our data suggest that suPD-L1 in the BM plasma of MM patients who have VGPR or better after AuHSCT could be used as a biomarker to predict outcome.enautologous transplantation; bone marrow plasma; multiple myeloma; prognosis; soluble PD-L1Autologous transplantation; Bone marrow plasma; Multiple myeloma; Prognosis; Soluble PD-L1[SDGs]SDG3CD8 antigen; programmed death 1 ligand 1; soluble programmed death 1 ligand 1; unclassified drug; CD274 protein, human; programmed death 1 ligand 1; tumor marker; adult; Article; autologous hematopoietic stem cell transplantation; bone marrow biopsy; bone marrow plasma; cancer growth; cancer patient; cancer survival; cell density; controlled study; cytotoxic T lymphocyte; enzyme linked immunosorbent assay; female; human; human cell; human tissue; major clinical study; male; middle aged; multiple myeloma; outcome assessment; overall survival; patient coding; plasma; predictive value; protein blood level; survival rate; survival time; treatment response; adolescent; aged; autotransplantation; blood; bone marrow; CD8+ T lymphocyte; cytology; disease exacerbation; disease free survival; hematopoietic stem cell transplantation; metabolism; multiple myeloma; multivariate analysis; prognosis; proportional hazards model; receiver operating characteristic; treatment outcome; young adult; Adolescent; Adult; Aged; B7-H1 Antigen; Biomarkers, Tumor; Bone Marrow; CD8-Positive T-Lymphocytes; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Plasma; Prognosis; Proportional Hazards Models; ROC Curve; Transplantation, Autologous; Treatment Outcome; Young Adult10.18632/oncotarget.1151927566569WOS:000387164700125